ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Deepak L. Bhatt(Brigham and Women's Hospital), Eamonn M.M. Quigley(Hagley Museum and Library), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Neena S. Abraham(Mayo Clinic in Florida), Francis K.L. Chan(Christian Health Association of Nigeria), David A. Johnson, James M. Scheiman(University of Michigan), Curt D. Furberg(National Heart Lung and Blood Institute), Elliott M. Antman(Brigham and Women's Hospital)
Cited by 845
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k